Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22 janv. 2025 16h00 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on January 21, 2025, it granted stock options to purchase an aggregate...
Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer
22 janv. 2025 08h00 HE
|
Pliant Therapeutics, Inc.
Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant...
Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
02 janv. 2025 08h00 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, is...
Pliant Therapeutics to Participate in Upcoming Investor Events
21 nov. 2024 08h00 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel...
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
18 nov. 2024 18h00 HE
|
Pliant Therapeutics, Inc.
INTEGRIS-PSC featured in an oral late breaker presentation SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology...
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
07 nov. 2024 16h05 HE
|
Pliant Therapeutics, Inc.
BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant...
Pliant Therapeutics to Participate in the Stifel Healthcare Conference
06 nov. 2024 08h00 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that Keith Cummings, M.D., Chief Financial Officer, and Greg Cosgrove, M.D. FCCP,...
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024
17 oct. 2024 08h00 HE
|
Pliant Therapeutics, Inc.
INTEGRIS-PSC to be featured in an oral presentation on Monday, November 18 SOUTH SAN FRANCISCO, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage...
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
01 oct. 2024 16h35 HE
|
Pliant Therapeutics, Inc.
Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc....
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
30 sept. 2024 16h45 HE
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on September 30, 2024 it granted stock options to purchase an aggregate...